Navigation Links
Gulf Coast Hospital Chooses Global Med Technologies(R)' Blood System
Date:11/24/2008

West Cal Cam becomes 181st Site in Southeast to Choose SafeTrace Tx(R)

DENVER, Nov. 24 /PRNewswire-FirstCall/ -- Global Med Technologies(R), Inc. ("Global Med") (OTC Bulletin Board: GLOB), an international e-Health, medical information technology company, today announced that its Wyndgate Technologies(R) ("Wyndgate") division has licensed SafeTrace Tx transfusion management software to West Calcasieu Cameron Hospital ("West Cal Cam") of Sulphur, Louisiana. Terms of the agreement were not disclosed.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040226/GLOBALMEDLOGO)

Ms. Tiffany K. Martin, Laboratory Director for West Calcasieu Cameron Hospital, stated, "After converting our lab from paper processes to the Orchard Harvest laboratory information system (LIS) four years ago, our administration recognized the need for a robust transfusion management system to manage our blood bank. We discovered that Wyndgate's SafeTrace Tx interfaced well with Orchard and with McKesson, our hospital information system vendor."

Ms. Martin continued, "Quality is the most important aspect for us in our lab. We were concerned about the numerous areas in the process where errors could be life-threatening. With automated systems such as SafeTrace Tx, built-in safety features and hard stops are typically available to help us detect and avoid errors. We were also excited about the ease of use and efficiencies built into the system, such as the Patient-At-A-Glance Bar(R), which allows us to view critical patient information in one location without pulling up charts."

SafeTrace Tx is a blood management software system designed to raise the standard of care for patients, improve safety, reduce waste and increase efficiency. SafeTrace Tx provides comprehensive tracking of orders, specimens, blood prod
'/>"/>

SOURCE Global Med Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Blissport Unveils the Best Honeymoon Destinations on Italy's Adriatic Coast for 2009
2. AlphaDetail, Inc. Continues Bi-coastal Expansion
3. Oaks Development Group Closes on 2.1 Acres for Medical Office Building in Palm Coast, FL
4. Gulf Coast Dialysis Caregivers, Volunteers Brace for Hurricane Ike; Prepare to Maintain Power, Continued Access for Patients to Life-Saving Treatment
5. Nurse Alliance of SEIU Healthcare Mobilizing RNs and Medical Supplies to Gulf Coast Areas in Advance of Hurricane Gustav
6. Coastal Center for Obesity Offers Hispanics Weight Loss Surgery with a Warranty
7. West Coast Bank Sponsors LifeWorks Northwest Programs for Children in Low-Income Housing Communities
8. American Red Cross on the Gulf Coast: Storms Coming and Going
9. Valley Forge Medical Center and Hospital to Become the First Addiction-Free Pain Management Center of Excellence on the East Coast; Will Host Three Day Professional Training Seminar.
10. Oregon Cosmetic Vein Center Opens in Portland, Among First on West Coast to Offer Brand New, FDA-Approved Procedures and Technologies
11. Vancouver Coastal Health Authority Makes Waves With Patient Flow

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/8/2009)...UCW Academy of Health holds open house at Victoria...ocus) November 8, 2009 -- UCW Academy of Health in...Columbia’s health care industry to attend th...25, 2009. , ,UCW Academy of Health, which offers ...and social services, designs its programs to meet ...
(Date:11/8/2009)...New book called "Preventing and Healing AIDS ...raldo shows that AIDS is a result of multiple, rep...ed immune system stressor agents, which can be eit...l, emotional. , Oakland,...; 8, 2009, cell biologists, physicians, chemists a...
(Date:11/8/2009)...PRNewswire-USNewswire/ -- Today, the House of Repr...kemper, Smith, Ellsworth and Lipinski amendment to.... 3962). The amendment maintains the current polic...or benefits packages that include abortion. It cla...fordability credits and those who do not, can with...
(Date:11/8/2009)...sage of H.R. 3961 to Secure the Stability of Medic... -- Statement Attributable to: J. James Rohack, M.... (Logo: http://www.newscom.com/cgi-bin/prnh/2008...of the House health reform bill, which will help i...ns and calls for swift passage of H.R. 3961 to sec...
(Date:11/8/2009)...ov. 8 March of Dimes ho...eon to recognize prominent individuals who are cel...ole models for March of Dimes commitment to improv...imes November Prematurity Awareness Month campaign...n the fight for preemies! ,, (Photo: http://w...
Breaking Medicine News(10 mins):Health News:College Invites Public to Explore Career Options in Health Care 2Health News:Revolutionary New Views on AIDS Highlight the Rethinking AIDS 2009 Congress; Emotional Issues can be a Significant Contributing Factor 2Health News:Revolutionary New Views on AIDS Highlight the Rethinking AIDS 2009 Congress; Emotional Issues can be a Significant Contributing Factor 3Health News:Family Research Council Praises Passage of Pro-life Amendment to Health Care Bill 2Health News:AMA Hails House Passage of Health Reform Bill (H.R. 3962) 2Health News:Hollywood Stars Joined in a Celebration of Babies 2Health News:Hollywood Stars Joined in a Celebration of Babies 3
...) --,HearAtLast Holdings, Inc. is proud to announc...art Canada (NYSE: WMT ) to open its 16th hearing-...located at 255 Silver Linden,Dr. in Richmond Hill,... its option under a master licensing agreement wit...
...standard being adopted worldwide by, pharmaceutica... confirming digital iden...ms,(Nasdaq: ALDN ), an information security leade... hardware product,to be certified under the recent...
...Diverse Expertise, MIAMI, Dec. 9 Novis Pharmaceu...oducts to healthcare providers, is pleased,to anno...e President of,Human Resources. Ms. Lopez was most...ating from Florida International,University (FIU)....
...eruse of colorectal cancer screening procedures am...n the January 15, 2008 issue of CANCER, a peer-rev... that only 25 percent of Medicare patients receive... States. The American Cancer Society estimates tha...
... believe or disbelieve a statement is a powerful f...t the basis of these states in the brain is not ye...lief and uncertainty activate distinct regions of ... the Annals of Neurology ( http://www.interscience...
...sone improved pre, - and post-stem cell transplan... dexamethasone -, ATLANTA, Dec...M ) reported the presentation of results from an i...nd,dexamethasone (VcTD) to thalidomide and dexamet...
Other Medicine News:Health News:HearAtLast Continues Expansion Announcing Opening of New Clinic Location in Sam's Club in Richmond Hill, Ontario 2Health News:HearAtLast Continues Expansion Announcing Opening of New Clinic Location in Sam's Club in Richmond Hill, Ontario 3Health News:HearAtLast Continues Expansion Announcing Opening of New Clinic Location in Sam's Club in Richmond Hill, Ontario 4Health News:Aladdin eToken First Strong Authentication Device to Achieve Certification from the SAFE-BioPharma Association 2Health News:Aladdin eToken First Strong Authentication Device to Achieve Certification from the SAFE-BioPharma Association 3Health News:Aladdin eToken First Strong Authentication Device to Achieve Certification from the SAFE-BioPharma Association 4Health News:Novis Pharmaceuticals Hires Lisa Lopez 2Health News:Many Medicare beneficiaries not receiving colorectal cancer screening 2Health News:Belief, disbelief and uncertainty activate distinct brain regions 2Health News:Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma 2Health News:Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma 3Health News:Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma 4Health News:Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma 5Health News:Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma 6
(Date:11/6/2009)...M, N.C., Nov. 6 Oxygen B...day announced that a previously approved reverse s...tart of trading on Monday, Nov. 9, 2009 on a 1-for...Inc. shares will trade under the new symbol OXBT. ...P 20 9, when the split becomes effective. ,, "T...
(Date:11/6/2009)...STOWN, N.J., Nov. 6 Wats...specialty pharmaceutical company, announced today ...cutive officer, will provide an overview and updat...8th Annual Healthcare Conference on Wednesday, Nov...,, This presentation will be webcast live and c...
(Date:11/6/2009)...ESTON, S.C., Nov. 6 T...g in South Carolina and Georgia throughout the wee...elp uninsured and financially-struggling patients ...iption medicines for free or nearly free. With the...nt, the Partnership for Prescription Assistance (P...
Breaking Medicine Technology:Oxygen Biotherapeutics, Inc. Announces 1:15 Reverse Stock Split to Take Effect Nov. 9, 2009 2Oxygen Biotherapeutics, Inc. Announces 1:15 Reverse Stock Split to Take Effect Nov. 9, 2009 3Partnership for Prescription Assistance Prepared to Help Southern Workers Hurt by Recession 2Partnership for Prescription Assistance Prepared to Help Southern Workers Hurt by Recession 3Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes 4918 1Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes 4918 2Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes 4918 3Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes 4918 4New Large Scale Global Study Provides Additional Information About an Intensified Dose Regimen of PLAVIX 28R 29 in Acute Coronary Syndrome Patients U 4917 1New Large Scale Global Study Provides Additional Information About an Intensified Dose Regimen of PLAVIX 28R 29 in Acute Coronary Syndrome Patients U 4917 2New Large Scale Global Study Provides Additional Information About an Intensified Dose Regimen of PLAVIX 28R 29 in Acute Coronary Syndrome Patients U 4917 3New Large Scale Global Study Provides Additional Information About an Intensified Dose Regimen of PLAVIX 28R 29 in Acute Coronary Syndrome Patients U 4917 4New Large Scale Global Study Provides Additional Information About an Intensified Dose Regimen of PLAVIX 28R 29 in Acute Coronary Syndrome Patients U 4917 5Get Ready for Ragweed 55647 1Get Ready for Ragweed 55647 2
... Italy, April 26 Schering-Plough Corporation,(NYS...ed interim analysis of,an ongoing Phase II study o... protease inhibitor, in 595 treatment-naive patien... were presented at the 43rd Annual,Meeting of the ...ASL). The,ongoing study evaluates boceprevir in 28...
...Large Study Comparing Leading Hepatitis C Therapie...ide Clinical Practice, MILAN, Italy, April 26 Fi...andomized, clinical study comparing the,leading th...day at the 43rd,Annual Meeting of the European Ass...ing important insights that may help guide clinica...
Other Medicine Technology:Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 2Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 3Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 4Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 5Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 6Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 7Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 8Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 9Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 2Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 3Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 4Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 5Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 6Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 7Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 8Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 9Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 10
...o-Surgery provides clip appliers in 10mm and 5mm s...iers provide precise clip placement., ,The ALLPOR...e preloaded, single-trigger instruments are design... a 5mm trocar, through a 5mm reducer cap in a larg...
...P-HS assay utilizes turbidimetric immunoassay meth...uring over the range of 0.2-28.0 mg/dL. This assay...to most clinical chemistry analyzers. The Wako CRP...ecision, linearity, correlation, and sensitivity. ...
LabDAQ3 Laboratory Information System
...e for laboratories to work more efficiently has ne...e solutions. With the COBAS INTEGRA® 400 plus,...ies, robotic handling of reaction cuvettes and imp...broad menu and ease-of-use required for true workl...
Medicine Products: